Drug Database
HO

hormone patches (Lyrelle / Lyrelle 50 / Lyrelle 80)

✓ Approved

Shire · ESR1 · Small Molecule

What is hormone patches?

hormone patches is a small molecule developed by Shire. It is approved for therapeutic indications via transdermal.

Drug Profile

Brand NamesLyrelle, Lyrelle 50, Lyrelle 80
CompanyShire
Drug ClassSmall Molecule
Molecular TargetESR1, PGR
RouteTransdermal
StatusApproved

Mechanism of Action

Molecular Targets

hormone patches acts on 2 molecular targets:

ESR1estrogen receptor 1 (ER, ESR)
PGRprogesterone receptor (NR3C3, PR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

hormone patches is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Surgical and medical proceduresHormone replacement therapy✓ Approved

Related Research Articles

PubMedJournal of plant research2026-09-20

Allelopathic effects and phytochemical analysis of Coleanthus subtilis as possible factors involved in its colonization success.

Klink Agnieszka A, Polechońska Ludmiła L, Gleńsk Michał M, Gola Edyta Magdalena EM et al.

Coleanthus subtilis is a globally rare therophyte growing on exposed bottoms of water reservoirs and riverbanks. Despite its small size and ephemeral nature, it shows a potential to conquer new areas and can dominate phytocoenoses of small wetland therophytes and pioneer the land interface zones of lakes, pools and ponds. However, features enabling its spread and dominance in patches remain poorly understood. Also, the composition of biologically active compounds of the species has not been characterized in detail so far. Therefore, we assessed the species allelopathic potential as referred to the presence of biologically active compounds and ecotoxicity. Several natural products belonging to benzoxazinone derivatives, phenolic compounds, and carboxylic acids were identified in this species, which are likely to have allelopathic potential. The results of phytotoxic tests showed that water extract of C. subtilis induced a delay in germination of the model plant Sinapis alba, and, at concentrations higher than 4%, caused a significant reduction in the percentage of germinated seeds. In addition, root growth of S. alba was inhibited at concentrations of the extract greater than 4%. Oppositely, the growth of model plant hypocotyl was stimulated by low concentrations (< 4%) of the C. subtilis water extract. By showing the allelopathic potential, our results shed new light on the C. subtilis performance and absolute dominance in some patches of muddy vegetation.

PubMedCureus2026-09-20

Thyroid Hormone Levels and Its Co-relation With Human Chorionic Gonadotropin in Patients With Molar Pregnancy.

Singh Priyadarsini P, Behera Swayamprava S, Patra Lipsa L, Behuria Sasmita S et al.

Introduction Gestational trophoblastic disease (GTD) is characterized by abnormal trophoblastic proliferation, with hydatidiform mole being its most common form. Markedly elevated serum human chorionic gonadotropin (hCG) concentrations in molar pregnancy can stimulate thyroid-stimulating hormone receptors, resulting in thyroid dysfunction. This study aimed to evaluate thyroid hormone levels and their correlation with serum β-human chorionic gonadotropin (β-hCG) concentrations in patients with molar pregnancy and to compare thyroid function between complete and partial hydatidiform mole. Materials and methods This prospective observational study was conducted in the Department of Obstetrics and Gynaecology, Srirama Chandra Bhanja (SCB) Medical College and Hospital, Cuttack, Odisha, India, from January 2022 to December 2023. Eighty-eight women with histopathologically confirmed hydatidiform mole were included after excluding 26 patients who had received initial treatment elsewhere and were referred exclusively for oncological management. Serum β-hCG, thyroid-stimulating hormone (TSH), free triiodothyronine (free T3), free thyroxine (free T4), total triiodothyronine (total T3), and total thyroxine (total T4) were measured before uterine evacuation. Thyroid hormone profiles were compared between complete and partial mole, and correlations between serum β-hCG and thyroid hormone parameters were analyzed using Pearson's correlation coefficient. Results Among 15,844 deliveries, 88 women with histopathologically confirmed hydatidiform mole were analyzed, yielding a hospital-based frequency of 5.5 per 1,000 deliveries. Complete mole constituted 57 (64.8%) cases and partial mole 31 (35.2%). Patients with complete mole had significantly lower TSH (0.82±0.71 vs. 1.96±0.82 µIU/mL; p<0.001) and significantly higher free T3, free T4, total T3, total T4, and β-hCG levels than those with partial mole (all p<0.001). Serum β-hCG demonstrated a significant negative correlation with TSH (r=-0.61; p<0.001) and positive correlations with free T3 (r=0.73), free T4 (r=0.69), total T3 (r=0.65), and total T4 (r=0.67) (all p<0.001). Conclusion Complete hydatidiform mole was associated with significantly higher serum β-hCG concentrations and more pronounced thyroid dysfunction than partial hydatidiform mole. Serum β-hCG concentrations demonstrated a significant negative correlation with TSH and positive correlations with free and total T3 and T4 levels, supporting a close association between trophoblastic activity and thyroid function. These findings suggest that thyroid dysfunction may be particularly relevant in women with complete hydatidiform mole or markedly elevated serum β-hCG concentrations; however, larger multicentric studies with adjustment for potential confounding factors and longitudinal follow-up are warranted to clarify the clinical significance of these associations.

PubMedUrologie (Heidelberg, Germany)2026-09-20

[Gender-affirming hormone therapy: state of the art].

Bischoff Jenny J

Gender incongruence affects approximately 0.6% of the population in Germany and, when accompanied by significant psychological distress, may constitute an indication for gender-affirming hormone therapy (GAHT). The increasing diversity of gender identity has led to a more individualized approach to hormone therapy. The decision to initiate treatment is based on the expected reduction in gender-related dysphoria due to hormonal treatment. Treatment is carried out in accordance with guidelines and is tailored to the wishes and goals of the person seeking treatment. Various estradiol preparations and antiandrogenic substances can be used to achieve feminization. Masculinizing therapy relies primarily on testosterone. For non-binary individuals, GAHT is usually administered at lower doses and typically focuses on specific aspects of gender alignment. The therapeutic effects usually develop slowly but can be irreversible and significant. Risks should be assessed in advance, and patients should be informed about potential adverse effects. Monitoring and adjustment of treatment take place at specified regular intervals. Adjustments and support throughout the course of treatment-ranging from fertility preservation to cancer screening-are key components of comprehensive care in patients undergoing GAHT. Although the evidence regarding GAHT has improved significantly in recent years, large-scale studies are still lacking for many aspects.

PubMedCureus2026-09-20

Recurrent Deep (Aggressive) Angiomyxoma of the Pelvis: Serial MRI Documentation of Sustained Complete Radiologic Response During Eight Years of Gonadotropin-Releasing Hormone (GnRH) Agonist Therapy.

Fevereiro Beatriz B, Fonseca Ricardo R, Cunha Teresa Margarida TM

Deep (aggressive) angiomyxoma is a rare mesenchymal tumor that primarily affects premenopausal women and is frequently misdiagnosed because of its deep pelvic location, indolent growth, and nonspecific clinical presentation. It is typically multicompartmental and demonstrates a characteristic laminated ("swirled") appearance on T2-weighted magnetic resonance imaging (MRI), reflecting alternating myxoid and fibrous stromal components. Local recurrence is common after surgical resection, making long-term imaging surveillance essential. Tumor expression of estrogen and progesterone receptors provides a biological rationale for hormonal therapy. We report a case of recurrent pelvic deep (aggressive) angiomyxoma in a 45-year-old woman who achieved complete and sustained radiologic remission documented by serial MRI throughout 8 years of continuous gonadotropin-releasing hormone (GnRH) agonist therapy. This uncommon long-term outcome highlights both the potential for durable disease control with hormonal therapy in deep (aggressive) angiomyxoma and the value of MRI for longitudinal assessment of treatment response.

PubMedJournal of pediatric endocrinology & metabolism : JPEM2026-09-20

Anti-Müllerian hormone levels in girls with precocious puberty.

Hepokur Merve Nur MN, Çamaş Aşan Önder AÖ, Taniş Gözde G, Çiçek Burçin B et al.

We aimed to evaluate the relationship between anti-Müllerian hormone (AMH) levels in cases of central precocious puberty (CPP), premature adrenarche (PA), and isolated premature thelarche (IPT) and those of healthy controls (HC). A total of 153 girls (40 PA, 39 CPP, 39 IPT, and 35 HC) were included in the study. AMH levels were assessed using the ELISA method. The mean age of all participants was 7.19 ± 0.63 (5.0-8.0) years. Height SDS was higher in the puberty and puberty variant groups compared with the healthy group. This difference was found to be statistically significant between the CPP and HC groups. Obesity was present in 20 of all participants (13 %). AMH levels were 0.125 ± 0.154, 0.086 ± 0.072, 0.084 ± 0.074, and 0.069 ± ;0.060 ng/mL in PA, PT, CPP, and HC groups, respectively. Although AMH levels were higher in the PA group, there was no statistically significant difference among the four groups. A weak negative correlation was found between AMH levels and BMI SDS (body mass index standard deviation score). AMH levels do not differ between prepubertal girls and those diagnosed with central precocious puberty or a variant of puberty of the same age.

PubMedGeoHealth2026-09-20

Beyond Green Cover: Links Between Greenspace Morphology, Configuration, and Heat-Related Illness in Arizona.

Wang Huaqing H, Li Shujuan S, Gholami Simin S, Hoover Joseph J et al.

Residential greenness has been associated with reduced heat-related illness, yet the specific role of greenspace morphology at the neighborhood scale remains insufficiently understood. This study quantified the relationship between heat-related illness and multiple dimensions of greenspace morphology using an 8-year (2016-2023) unbalanced panel data set comprising 19,021 block-group-year observations across 2,427 census block groups in Arizona, USA. One meter high-resolution National Agricultural Imagery Program aerial imagery was classified to calculate greenspace percentage, number of greenspaces, average size, shape complexity, connectedness, and distantness, at the block group level. We applied conditional spatial autoregressive models with a negative binomial distribution to estimate associations between each morphology metric and yearly heat-related illness counts, adjusting for sociodemographic and geographic covariates. Additional sensitivity analyses evaluated the robustness of findings to overall greenspace amount, local climatic conditions, and alternative exposure specifications. We found higher greenspace percentage, aggregation, shape complexity, connectedness, and density were consistently associated with lower heat-related illness risk. A one-standard deviation increases in shape complexity corresponded to a 12.4% decrease in expected heat-related illness counts (IRR = 0.876, 95% CI: 0.834-0.921). Similarly, increases in greenspace percentage (14.6% decrease; IRR = 0.855, 95% CI: 0.827-0.885), number of greenspace patches (3.7% decrease; IRR = 0.963, 95% CI: 0.937-0.990), average size (4.5% decrease; IRR = 0.955, 95% CI: 0.923-0.989), and connectedness (5.5% decrease; IRR = 0.945, 95% CI: 0.918-0.972) were all protective. In contrast, larger inter-greenspace distances were associated with increased heat-related illness risk (6.1% increase; IRR = 1.061, 95% CI: 1.033-1.091). These associations were generally robust to additional adjustment for local climatic conditions and overall greenspace area. Our findings highlight the critical importance of multiple dimensions of greenspace morphology in relation to heat-related health risks. These results suggest that heat-reduction planning with greening initiatives should consider not only the amount of greenspace but also its spatial configuration to maximize cooling and result in health benefits.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about hormone patches